A5032091930- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Liver Disease and Transplantation
- Hepatitis B Virus Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Diseases and Immunity
- Diet, Metabolism, and Disease
- Hormonal Regulation and Hypertension
- Renin-Angiotensin System Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Apelin-related biomedical research
- Vitamin D Research Studies
- Gallbladder and Bile Duct Disorders
- Microscopic Colitis
- Organ Transplantation Techniques and Outcomes
- Pancreatic and Hepatic Oncology Research
- Inflammatory Bowel Disease
- Nutrition and Health in Aging
- Hepatitis Viruses Studies and Epidemiology
- Liver physiology and pathology
- Cardiovascular Function and Risk Factors
- COVID-19 Clinical Research Studies
- Pediatric Hepatobiliary Diseases and Treatments
- Drug-Induced Hepatotoxicity and Protection
- Gastrointestinal disorders and treatments
Alfred Health
2020-2025
Monash University
2016-2025
The Alfred Hospital
2020-2025
Northern Health
2008-2025
Monash Alfred Psychiatry Research centre
2022-2023
Northern Hospital
2022
Eastern Health
2012-2021
Box Hill Hospital
2009-2017
657 Oslo
2016
Austin Hospital
2005-2012
Objective We evaluated the influence of renin–angiotensin system (RAS) on intestinal inflammation and fibrosis. Design Cultured human colonic myofibroblast proliferation collagen secretion were assessed following treatment with angiotensin (Ang) II Ang (1–7), their receptor antagonists candesartan A779, ACE inhibitor captopril. Circulating RAS components in patients without IBD. Disease outcomes IBD treated inhibitors blockers (ARBs) retrospective studies. Results Human was reduced by (1–7)...
Angiotensin-converting enzyme 2 (ACE2), its product, angiotensin-(1-7) and receptor, Mas, may moderate the adverse effects of angiotensin II in liver disease. We examined expression these novel components renin system (RAS) production vasoactive bile duct ligated (BDL) rat.BDL or sham-operated rats were sacrificed at 1, 2, 3 4 weeks. Tissue blood collected for gene expression, activity peptide measurements. In situ perfused livers used to assess their on portal resistance.Hepatic ACE2...
Vitamin D may mediate immunomodulatory effects in patients with inflammatory bowel disease (IBD). The relationships between activity and circulating levels of total, free, bioavailable 25(OH) vitamin (25(OH)D) are poorly defined. aim this study was to measure components the axis IBD healthy controls correlate these markers activity, adjusting for potential confounders.Clinical data were obtained serum analyzed 25(OH)D D-binding protein controls. Markers systemic intestinal (fecal...
ABSTRACT Background and Aims Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver condition that has significant association with inflammatory bowel disease (IBD) impaired health‐related quality of life (HRQOL). We aimed to characterise compare validated PSC IBD patient‐reported outcomes (PRO) determine if PRO correlated the severity disease. Methods conducted multicentre, prospective cohort study in Australia enrolling adult patients from December 2019 August 2023. Consecutive...
Ang-(1–7) (angiotensin-1–7), a peptide product of the recently described ACE (angiotensin-converting enzyme) homologue ACE2, opposes harmful actions AngII (angiotensin II) in cardiovascular tissues, but its role liver disease is unknown. The aim present study was to assess plasma levels human and determine effects experimental fibrosis. Angiotensin were measured cirrhotic non-cirrhotic patients with hepatitis C. on fibrosis determined using rat BDL (bile-duct ligation) model. Liver...
The relationship between intestinal inflammation and circulating components of the renin-angiotensin system (RAS) is poorly understood.Demographic clinical data were obtained from healthy controls patients with inflammatory bowel disease (IBD). Plasma concentrations classical RAS (angiotensin-converting enzyme (ACE) angiotensin II (Ang II)) alternative (ACE2 (1-7) (1-7))) analysed by radioimmuno- enzymatic assays. Systemic was assessed using serum C-reactive protein (CRP), white cell count,...
Abstract Background/Aims Endoscopic screening for high‐risk gastro‐oesophageal varices ( GOV ) is recommended compensated cirrhotic patients with transient elastography identifying increasing numbers of cirrhosis without portal hypertension. Using liver stiffness measurement LSM ± platelet count, the aim was to develop a simple clinical rule exclude presence in Child–Pugh A cirrhosis. Methods retrospective analysis 71 diagnosed by >13.6 kP a) who underwent gastroscopy conducted....
Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths both globally and in Australia. Surveillance for HCC at-risk populations allows diagnosis at an early stage, when potentially curable. However, most Australians diagnosed with die the or liver disease. In changing landscape management, unique challenges may lead to clinical practice variation. As result, there need identify best management Australian context. This consensus statement has been developed health professionals...
The prevalence of hepatitis B virus (HBV) infection in Australia is nearly 1%. In certain well defined groups the far greater, yet an estimated 27% people living with HBV remain undiagnosed. Appropriate screening improves detection, increases opportunity for treatment, and ultimately reduces significant morbidity mortality associated development liver fibrosis hepatocellular carcinoma (HCC).This statement highlights important aspects management Australia. There have been recent changes...
Current guidelines recommend long-term nucleot(s)ide analogue (NA) therapy for patients with HBeAg-negative chronic hepatitis B (CHB). However, disease remission has been described after stopping NA therapy, as well HBsAg loss.We performed a prospective multi-centre cohort study of therapy. Inclusion criteria were CHB, the absence cirrhosis and HBVDNA<lower limit quantification ≥18 months. We assessed virological biochemical outcomes including loss, restart rates, over 96 weeks.In total, 110...
Abstract Background & Aims The burden of metabolic dysfunction‐associated steatotic liver disease (MASLD) is growing rapidly, as the number older adults globally. However, relatively few studies have been performed evaluating prevalence and risk factors for MASLD in adults. As such, we aimed to identify adults, well sociodemographic, clinical, functional biochemical associations. Methods study population included without a history cardiovascular disease, dementia or independence‐limiting...
Abstract Background The burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is growing rapidly, including among older adults. number adults also rising with concomitantly increasing rates age-related physical and cognitive dysfunction. However, data on whether MASLD affects function in limited. As such, we aimed to identify prevalent influences the risk incident disability or dementia initially healthy Methods A post-hoc analysis participants from ASPREE-XT cohort...
Hepatocellular carcinoma (HCC) incidence is rising rapidly in many developed countries. Primary epidemiological data have invariably been derived from cancer registries that are heterogeneous quality and registration methodology; not adopted current clinical diagnostic criteria for HCC still rely on histology classification. We performed the first population‐based study Australia using criteria, hypothesizing may be higher than reported. Incident cases of (defined by American Association...
Objectives: To determine the factors associated with survival of patients hepatocellular carcinoma (HCC) and effect HCC surveillance on survival. Design, setting participants: Prospective population-based cohort study newly diagnosed in seven tertiary hospitals Melbourne, 1 July 2012 – 30 June 2013. Main outcome measures: Overall (maximum follow-up, 24 months); participation Results: 272 people were incident during period; most common risk hepatitis C virus infection (41%), alcohol-related...